NEWTOWN,
Pa., Sept. 11, 2024 /PRNewswire/ --
Edelson Lechtzin LLP, a leading class action law firm, is
investigating securities fraud claims on behalf of all
investors of Agenus, Inc. ("Agenus") (NASDAQ: AGEN) between
January 23, 2023, and July 17, 2024, inclusive (the "Class
Period").
Investors who purchased Agenus stock may move the U.S. District
Court for the District of Massachusetts to appoint them as lead
plaintiff, no later than November 5,
2024. Please contact Edelson Lechtzin LLP to
discuss your investment losses at 844-696-7492, or by e-mail
at elechtzin@edelson-law.com. A copy of the Complaint can be
found HERE.
Background on Agenus, Inc.
Agenus is a biotechnology company headquartered in Lexington, Massachusetts that is involved in
the discovery of immune-oncology ("I-O") products. One of its
product candidates, balstilimab, is being tested for treating
second-line cervical cancer. Another product, botensilimab, is
being tested for treating pancreatic cancer and melanoma. Agenus
also is focused on a combination of botensilimab and balstilimab as
a potential treatment for metastatic colorectal cancer.
The Securities Fraud Claims
The Complaint alleges that during the Class Period,
Defendants made materially false and misleading statements
regarding the Agenus's business, operations, and prospects.
Specifically, Defendants failed to disclose to investors that: (i)
the combination therapy of botensilimab and balstilimab was less
effective than Defendants had led investors to believe; and (ii)
accordingly, botensilimab and balstilimab's clinical results, as
well as their regulatory and commercial prospects, were
overstated.
On July 18, 2024, Agenus issued a
statement about its meeting with the U.S. Food and Drug
Administration regarding the progress of its treatment for adults
with a specific type of colorectal cancer. The FDA recommended not
submitting the results for accelerated approval because they
believed that the response rates observed may not lead to improved
survival. On this news, Agenus's stock price fell $10.43 per share, or 58.83%, to close at
$7.30 per share on July 18, 2024.
For more information, please contact:
Marc H. Edelson, Esq.
Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 or 215-867-2399 ext. 1
Email: medelson@edelson-law.com
Email: elechtzin@edelson-law.com
Web: www.edelson-law.com
Edelson Lechtzin LLP is a leading class action law firm with
offices in Pennsylvania and
California. In addition to cases
involving securities and investment fraud, our lawyers
focus on class and collective litigation in cases alleging
violations of the federal antitrust laws, employee benefit plans
under ERISA, wage theft and unpaid overtime, consumer
fraud, and dangerous and defective drugs and medical
devices.
This press release may be considered Attorney Advertising in
some jurisdictions. No class has been certified in this case, so
you are not represented by counsel unless you retain one. You may
select counsel of your choice. You may also remain an absent class
member and do nothing at this point. Your ability to share in any
potential future recovery is not dependent upon serving as lead
plaintiff.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/agen-investor-alert-edelson-lechtzin-llp-urges-agenus-inc-nasdaq-agen-shareholders-to-seek-legal-counsel-about-the-pending-securities-fraud-class-action-302245544.html
SOURCE Edelson Lechtzin LLP